Anti-DRAK1(NT)Antibody
CatalogNo.:2147
Size:100ugIgGinPBS,pH7.4,purifiedbyimmunoaffinitychromatography.
Certainserine/threonineproteinkinases,suchasASK-1andRIP,aremediatorsofapoptosis.Twonovelserine/threoninekinasesthatinduceapoptosishavebeenidentifiedanddesignatedDRAK1andDRAK2forDAPkinase–relatedapoptosis-inducingproteinkinases.DRAKscontainanN-terminalkinasedomainandaC-terminalregulationdomain.OverexpressionofDRAK1inducesapoptosis.DRAKshavehighsequencehomologytoDAPandZIPkinases,andtheyrepresentanovelfamilyofserine/threoninekinaseswhichmediateapoptosisthroughtheircatalyticactivities.
DRAK1islocatedincellnuclei,andthemRNAforDRAK1isubiquitouslyexpressedinhumantissues.
Antigen:Peptidecorrespondingtoaa5-19ofhumanDRAK1(accessionno.Q9UEE5).
HostSpecies:Rabbit
StABIlizers:None
Preservatives:0.02%sodiumazide.
ThisantibodyrecognizeshumanDRAK1(50kDa).Nocross-reactivitywithDRAK2,DAPorZIPkinases.
Forinvitroinvestigationaluseonly.Notforuseintherapeuticordiagnosticprocedures.
APPLICATIONSImmunoblotting:useat1ug/ml.
WesternblotanalysisofDRAK1in(A)MOLT4and(B)A431wholecelllysateswithDRAK1antibodyat1μg/ml.
Positivecontrol:WholecelllysatefromA431orMOLT4cells.
Immunocytochemistry:useat2ug/ml.
ImmunocytochemicalstainingofMOLT4cellsusingDRAK1antibodyat2μg/ml.
Thesearerecommendedconcentrations.Endusershoulddetermineoptimalconcentrationsfortheirapplications.
DiluteinPBSormediumwhichisidenticaltothatusedintheassaysystem.
Thisantibodyisstableforatleastone(1)yearat-20oC.Avoidmultiplefreeze-thawcycles.
